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Congenital ocular toxoplasmosis is a signifi-
cant cause of blindness. Retinochoroiditis is
the most common finding, but other ocular
manifestations include microphthalmus, nys-
tagmus, strabismus, and ptosis. The serologic
tests and lymphocyte stimulation test are the
most useful aids in making the diagnosis. Pyri-
methamine, sulfonamides, and corticoste-
roids are useful to treat active lesions.
Primary care physicians, obstetricians, and
ophthalmologists may help to prevent trans-
mission of the disease and its serious ocular
sequelae.
Congenital toxoplasmosis was first identified in
1939 when Wolf et all established toxoplasmosis
as the cause of a meningoencephalitis and retino-
choroiditis. Later these investigators verified the
transmissibility of the disease.2 Evidence has ac-
crued and investigators have proposed theories
about the prevalence, manifestations, diagnostic
techniques, and therapeutics of toxoplasmosis.
This paper reviews these developments, with em-
phasis on the congenital ocular sequelae.
BIOLOGY
Toxoplasmosis, caused by the obligate intracel-
lular protozoan Toxoplasma gondii, occurs in
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many mammals and birds. The organism has three
infective forms: oocyst, free trophozoite, and tis-
sue cyst. The oocyst is ovoid, measures approxi-
mately 9 by 14 Am, and contains two separate
sporocysts.3 In the alimentary tract of the cat, the
definitive host of T gondii, the organism under-
goes a sexual cycle leading to the production of
oocysts that are passed in the feces. The oocysts
are presumed to be swallowed by (1) children
sucking their fingers, (2) persons who eat after
contact with soil or cat litter without first washing
their hands, and (3) persons who eat unwashed
vegetables.4'5 Also, flies and cockroaches are
believed to contaminate human food with viable
oocysts for up to 48 hours after contact with cat
feces.6,7
Trophozoites appear as elongated teardrops and
measure approximately 4 to 7 ,um by 2 to 4 ,m.
Cysts consist of toxoplasma aggregates containing
large glycogen granules. The encysted organism,
surrounded by a limiting structure that is partially
produced by the parasite, remains viable for the
life of the host.8'9 Raw or inadequately cooked
meat that contains toxoplasma cysts and tropho-
zoites is a frequent source of infection. It is
believed the organism may be transmitted through
handling of infected meat with failure to wash
hands afterwards.'0"'1
EPIDEMIOLOGY
Toxoplasmosis, a world-wide disease, is more
prevalent in temperate and tropical climates than
in cold climates. 12 Prevalence data concerning
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toxoplasmosis have shown wide variations, rang-
ing from 5 to 95 percent among young adults living
in different parts of the world.'3 These variations
may be related to factors such as differences in
meat-eating habits, degree of exposure to infec-
tious feces of cats, and temperatures that influence
the survival of the oocyst once outside the cat.
The serologic prevalence of toxoplasmosis, which
increases with age, is approximately 30 percent in
the US adult population.
In an extensive survey it was found that approx-
imately 70 to 80 percent of females enter repro-
ductive age without evidence of seroimmunity.
The incidence of primary infection in pregnant
women was approximately 1.25 percent per year. 14
The overall rate of transmission to the fetus from a
primary maternal infection has been found to be
approximately 40 percent, depending upon the
gestational age at the time of infection.'1315 First
trimester maternal infection appears to result in a
17 percent rate of fetal infection, whereas the risk
increases to 25 percent and 65 percent for the sec-
ond and third trimesters, respectively.16 The ob-
served incidence of congenital toxoplasmosis in a
prospective study was 1.1 per 1000 live births.
Therefore, of the 3.3 million live births per year in
the US, approximately 3300 infants are likely to be
infected congenitally with Toxoplasma.17
Although acquired toxoplasmosis is most often
asymptomatic, congenital infection more com-
monly presents with significant manifestations.
Congenital infection occurs only as a result of
maternal infection acquired during a current preg-
nancy.'5"17 There have been case descriptions of
congenital toxoplasmosis in siblings;1819 however,
no prospective study has shown a case of congeni-
tal toxoplasmosis that developed in the absence of
maternal infection during the current pregnancy.
Desmonts and Couvreur determined that the risk
of severe clinical disease in infants resulted from
maternal infection acquired during the second
through sixth months of gestation. Acquisition
later in pregnancy usually resulted in a subclinical
infection. 15
Perkins studied 150 cases of uveitis and found
that 21 percent were due to toxoplasmosis.20 In a
separate study, toxoplasmosis was seen to cause
19 percent of all chorioretinal scars suspected of
having an infectious etiology.2' Surveying schools
for the blind, Fair found 26 of 46 (56 percent) stu-
dents with visual impairment that was believed to
have resulted from congenital chorioretinitis.22
Only congenital cataract was a more frequent
cause of school admission than chorioretinitis.
Toxoplasmic retinochloroiditis, therefore, is a
significant world-wide public health problem.
CLINICAL MANIFESTATIONS
Approximately 20 to 30 percent of infants born
with congenital toxoplasmosis manifest severe
disease.23'24 Another 10 percent are born with ocu-
lar involvement, but without clinical evidence of
disease of other organ systems.24 The remaining 60
to 70 percent are asymptomatic at birth.23 How-
ever, a substantial proportion of asymptomatic
infants develop delayed adverse sequelae of the
congenital infection months to years later.25'26
Congenital toxoplasmosis is known to produce
a variety of disease processes. Central nervous
system involvement may cause cerebral calcifica-
tion, hydrocephaly or microcephaly, and psycho-
motor retardation. Commonly, nonspecific find-
ings of lymphadenopathy, hepatosplenomegaly,
rash, and anemia are present. However, retino-
choroiditis is the most common finding in congeni-
tal toxoplasmosis, occurring in about 80 percent of
cases.27 Retinochoroiditis may be asymptomatic,
or may cause various symptoms including blind-
ness.27 Though reintochoroiditis is common in
congenital toxoplasmosis, it is rarely recognized in
acquired systemic toxoplasmosis.28 It is believed
that most cases diagnosed as acquired toxoplasmo-
sis are actually recurrences ofcongenital infection.29
Retinochoroidal lesions caused by toxoplas-
mosis are characterized histologically by granu-
lomatous inflammation and necrosis of the retina
and choroid.30'31 The necrotic retina contains the
Toxoplasma. The lack of organisms in the choroid
suggests that the infection is principally retinal,
with secondary choroidal involvement. The lesion
contains epithelioid cells, lymphocytes, plasma
cells, and varying numbers of polymorphonuclear
leukocytes and eosinophiles. There is also out-
growth of granulation tissue into the vitreous,
which corresponds to raised masses seen oph-
thalmoscopically. The vast majority of ocular le-
sions involve the posterior pole, particularly the
macular region.22 Although there have been many
cases describing peripherally located lesions, it is
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believed that peripheral lesions are more common
in blacks than in whites. In a study of immigrants
to Great Britain from West Africa and the West
Indies, Chesterson and Perkins reported that pe-
ripherally situated lesions were found in 25.9 per-
cent of blacks and 3.8 percent of whites studied.32
Funduscopic findings of acute retinochoroidal
lesions reveal yellowish-white patches sometimes
accompanied by a small hemorrhage, an overlying
exudate, and vitreous opacities (Figure 1). Small
satellite lesions may surround the principal
foci.33'34 As the lesions become chronic, pigment
becomes visible at the margins.33 The lesions usu-
ally heal within a few weeks to several months.
The healed lesion is characterized by a whitish-
gray appearance with distinct but irregular borders
(Figure 2). The pigment at the margins becomes
more prominent and usually extends to the center
of the lesion. Peripapillary lesions are present in
approximately 20 percent of toxoplasmosis cases
with retinal involvement. Small peripapillary le-
sions can produce extensive visual field defects
resulting from destruction of the nerve fiber
layer.35
Nystagmus and strabismus are frequent symp-
toms of congenital toxoplasmosis. These symp-
toms may occur because of poor fixation due to
decreased central acuity from macular lesions or
loss of visual function from central nervous sys-
tem involvement.33 Ptosis associated with exotro-
pia may occur due to oculomotor nerve palsy.36
Other ocular complications include anterior uve-
itis, which is secondary to posterior disease,37 mi-
crophthalmus, and remnant of the hyaloid system.38
LABORATORY MANIFESTATIONS
Laboratory tests that have been used to diag-
nose a toxoplasmosis infection include (1) histo-
logic examination, (2) isolation of the parasite, (3)
skin test, (4) serodiagnosis, and (5) demonstration
in vitro of antigen-specific lymphocyte recogni-
tion. Histologic examination is only helpful retro-
spectively, since it is possible to examine the his-
tologic appearance of the granulomatous lesions
containing the toxoplasma only after enucleation
of the eye.
The organism may be isolated from digested
placental tissue. It then may be injected intraperi-
Figure 1. Focal hypopigmented lesion in the pos-
terior pole typical of acute to subacute stages of
inflammation
Figure 2. Chronic macular lesion with area of central
atrophy surrounded by zone of hyperpigmentation
toneally into laboratory mice whose lack of prior
infection has been established.15 However, this
test has utility only when the newborn is suspected
of havin'g congenital toxoplasmosis and the pla-
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centa is preserved for diagnostic purpose. Also,
this method is not routinely available clinically.
The skin test demonstrates hypersensitivity as a
result of cell-mediated immunity, similar to the tu-
berculin skin test. However, the reaction requires
several months to develop, and an unacceptably
large number of false-negative results have been
observed in one investigation.8
Serologic tests used for the diagnosis of toxo-
plasmosis include (1) the Sabin-Feldman dye test
(DT), (2) the conventional indirect fluorescent
antibody text, (3) the IgM-fluorescent antibody
test (IgM-IFA), (4) the complement fixation test,
and (5) the indirect hemagglutination test. The DT
and IgM-IFA tests are the most useful in diagnos-
ing congenital toxoplasmosis.
The DT is unsurpassed in sensitivity and speci-
ficity. Therefore it has become the reference sero-
logic procedure.8 It is performed by mixing the
patient's serum with a suspension of living toxo-
plasma organisms, human serum accessory factor,
and methylene blue dye.'7 The organisms fail to
stain with methylene blue dye in the presence of
IgG antibodies. The titer refers to the highest dilu-
tion at which 50 percent of the extracellular toxo-
plasma lose their affinity for the dye.39 In patients
with only retinochoroiditis, the DT titer is fre-
quently low. In one case cited, the DT titer was
positive only in undiluted serum and many toxo-
plasma were identified in the eye at autopsy.40
Therefore, a positive test at any titer is significant
when associated with a patient who has a fundus
lesion compatible with toxoplasmosis. In most
infections, IgM antibodies appear earlier and dis-
appear sooner than IgG antibodies. Also, IgM
antibodies do not normally cross the placenta.
Therefore, the IgM-IFA test may establish the
diagnosis sooner than the dye test.4' A major dis-
advantage is its lack of sensitivity-the IgM-IFA
test has been negative in a significant number of
infected children.42
The lymphocyte stimulation test (LST) is the
newest aid for the diagnosis of toxoplasmosis.
Since lymphocyte transformation reflects a spe-
cific immune response in the newborn, the test
measures the blastogenic response of lymphocytes
incubated with Toxoplasma antigen. The LST has
been found to be more sensitive than the IgM-IFA
test in infants older than three months;43 however,
further investigation is needed to define better the
sensitivity and specificity of this technique.
TREATMENT
Conventional anti-Toxoplasma drugs are active
only against the proliferative trophozoites and
have no effect on tissue cysts.44 Because of the
progressive nature of the disease and its tendency
toward delayed damage, some authors recom-
mend treatment regardless of symptoms or type of
lesion.'5'24'26 Others, however, believe treatment
should be instituted only under specified condi-
tions,35'37'45 which include the presence of (1)
active macular lesions, (2) active lesions within the
papillomacular bundle, (3) lesions threatening or
involving the optic nerve, or (4) lesions causing
massive vitreous reaction sufficient to cause sub-
sequent retinal detachment.
The preferred therapy is a combination of sul-
fonamides (sulfadiazine in particular) and pyri-
methamine (Daraprim) which acts synergistically
to block the conversion of para-aminobenzoic acid
to folinic acid.46 The mammalian host can utilize
preformed folinic acid whereas the toxoplasma
cannot.47 The recommended dosage for pyrimeth-
amine consists of a single loading dose of 1 mg/kg
and a maintenance dose of 0.5 mg/kg/d; for sulfa-
diazine the dosage is 100 to 150 mg/kg/d in four
divided doses. The disadvantage of therapy is that
pyrimethamine inhibits human folate metabolism
and thereby produces leukopenia and thrombo-
cytopenia. For this reason, the drug is adminis-
tered for no more than four consecutive weeks,
with a two- to three-week interval between treat-
ments. Folinic acid, 5 to 10 mg intramuscularly
three to four times per week during therapy, reduces
the frequency of complications without interfering
with the efficacy of the drug.
Corticosteroids should be used for active
vision-threatening lesions. Prednisone, 1 to 2
mg/kg/d, should be given in conjunction with sul-
fadiazine and pyrimethamine. Therapy should be
contained until healing is established, as evi-
denced by a well demarcated and pigmented le-
sion. However, sulfadiazine and pyrimethamine
may be discontinued only after the corticosteroids
are tapered.37'46
Immunocompromised patients and others that
cannot tolerate sulfadiazine and pyrimethamine
have benefited from other drugs. Spiramycin is a
macrolide antibiotic that is unavailable in the
United States, but has been used widely in
Europe. It is less toxic, but is much less effective
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than the preferred treatments of retinochoroidi-
tis.45 Some evidence supports treatment with clin-
damycin to resolve active toxoplasmic retinocho-
roiditis.4849 Clindamycin develops a high ocular
tissue concentration and is believed to be effective
in the chronically infected cyst containing retinocho-
roidal lesions.49 50 Although it carried a significant
risk of pseudomembranous colitis in adults, there
is not a high risk of this complication in children.
PREVENTION
Obstetricians can make a significant contribu-
tion to the prevention of toxoplasmosis. Pregnant
women should be instructed to (1) wash hands
thoroughly after handling raw meat, (2) eat only
well-cooked meat, (3) wear gloves while handling
material potentially infected with cat feces (eg, cat
litter boxes, soil, sand), (4) wash hands after han-
dling materials infected with cat feces, and (5) dis-
infect cat litter boxes with boiling water. In those
women identified as "high risk" (eg, due to cat
exposure or raw meat infestion during pregnancy),
serial toxoplasma antibody titers can be drawn to
detect acute subclinical infection.
The primary care physician can also make a
significant contribution. The presence of nonspe-
cific signs and symptoms at birth should prompt a
careful funduscopic examination. Establishing the
diagnosis in the early neonatal period may pre-
vent irreparable damage or further ocular tissue
destruction.
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